We are deeply saddened to learn that MS South Australia & Northern Territory (MS SA&NT) has entered into voluntary administration.
The McDonald Diagnostic Criteria for MS have been updated to help people get diagnosed faster and more accurately.
Reporting side effects, even minor ones, is one way people with MS can contribute to safer treatment for everyone.
CEO Rohan Greenland details the upcoming handover of the Blueprint for a National Action Plan for Neurological Conditions, a prod to government to recognise both the obligation and the economic imperative to deliver coordinated national action.
A new Australian study shows COVID-19 boosters improve protection against new variants for people with MS, even when taking immune-suppressing treatments.
People living with MS find MSReactor is a convenient and acceptable way to monitor changes in their thinking and memory over time.
The Pharmaceutical Benefits Advisory Committee has recommended subcutaneous ocrelizumab (Ocrevus®) be listed on the PBS for treating relapsing remitting MS.
The Government has announced changes to the NDIS aimed at slowing growth and making the scheme more sustainable. What are those changes and how will they impact Australians living with MS?
MS Australia announces the four recipients of the first round of Incubator Grants for 2025.
